Biologic And Small Molecule Drug Substance CDMO Selection Metrics Align

By Industry Standard Research

ISR’s annual CDMO Benchmarking research asks participants to identify the CDMO attributes that factor into their service provider selection decision. Four out of five of the top metrics sync up among drug substance outsourcers for biologics and small molecules. However, among large molecule outsourcers, a Track record for meeting quality performance metrics made the top five but landed in 8th position among small molecule outsourcers. Conversely, small molecule outsourcers prized a Proven ability to manufacture small molecule API while this attribute ranked 6th for biologic outsourcers.